Calendario›BIIB›Felzartamab · MYAMERGE
Felzartamab · MYAMERGE
Ensayo de BIOGEN INC. en Miastenia gravis generalizada.
Todo sobre el fármaco: Felzartamab.
- Fase
- Fase 2
- Estado
- Aún sin reclutar
- Participantes
- 75
- Fin del objetivo primario
- sep 2028
Título oficial en el registro (en inglés): A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en nov 2026.
De principio a fin
- Empieza el ensayo (nov 2026)
- Hoy
- Lectura de resultados sep 2028 (prevista)
Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.
Qué mide
Cohorte 1: Cambio desde el inicio en la puntuación total de la Escala de Actividades de la Vida Diaria de la Miastenia Gravis (MG-ADL) en la semana 26 (inicio y semana 26)
Qué se prueba
En este estudio se investigan los efectos de felzartamab en adultos con miastenia gravis generalizada.
Lo que dice el documentolearn more about the effects of felzartamab, also known as BIIB148, in adult participants with generalized myasthenia gravis, also known as gMG.
Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroIn this study, researchers will learn more about the effects of felzartamab, also known as BIIB148, in adult participants with generalized myasthenia gravis, also known as gMG. This is a type of autoimmune disease that affects the signals sent between nerve cells and the muscles. An autoimmune disease means the body's immune system attacks its own healthy cells. In people with gMG, the body's immune system makes abnormal antibodies that affect the signals that can be sent between the muscle and the nerves at the neuromuscular junction. The neuromuscular junction is where the nerve and muscle connect. The most common antibodies made in gMG are those that target 1 of 2 types of proteins - AchR (acetylcholine receptor) and MuSK (muscle-specific tyrosine kinase). In this study, researchers wanted to learn more about a study drug called felzartamab. Researchers think felzartamab may lower the amount of antibodies against AChR or MuSK and allow signals between muscles and nerves to be sent normally again. The main goal of the study is to compare the effects of felzartamab to a placebo on symptoms and daily living activities in adult participants with gMG. A placebo looks like the study drug but does not contain any medicine. The main question researchers want to answer is: * Does felzartamab increase the ability to perform daily activities after 26 weeks of treatment in participants with AChR antibodies? Researchers will also learn more about: * How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug. * How the body processes felzartamab * How felzartamab affects the participants' disease severity * How many participants' bodies make antibodies against felzartamab after treatment This study will be done as follows: * Participants will join the study after signing an informed consent form, also known as an ICF. * Participants will be screened to check if they can join the study. Participants will then be assigned to a study group based on the type of antibodies they have. * If participants have AChR antibodies, they will be randomly assigned to receive either felzartamab or a placebo. Neither the participants nor the researchers will know if participants are getting the study drug or the placebo. * If participants have MuSK antibodies, they will receive felzartamab. In this group, the participants, study doctor, and study staff know which drug the participant is taking. * Both felzartamab and the placebo will be given as an intravenous (IV) infusion, which involves giving the drug into a vein. * During the study, participants will have regular clinic visits and phone calls. At the visits, participants will have blood and urine samples taken and will also have their overall health checked. The participants will also be asked questions about how they are feeling and how their gMG is affecting their daily lives. * After their last dose, participants will enter a follow-up safety period for more testing and monitoring of their health.
Más ensayos de BIIB
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Diranersen · CELIA | Fase 2 | En marcha, sin reclutar | mar 2026 (real) |
| BIIB142 | Fase 1 | Reclutando pacientes | ago 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · TOPAZ-2 | Fase 3 | En marcha, sin reclutar | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · TOPAZ-1 | Fase 3 | En marcha, sin reclutar | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Litifilimab · AMETHYST | Fase 2/3 | En marcha, sin reclutar | oct 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Felzartamab · TRANSCEND | Fase 3 | En marcha, sin reclutar | dic 2026 (prevista) |
Todos los de BIIB, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07939802), actualizada en nov 2026.